Caryn M Upton (Caryn Upton)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 20

Top Topics

Cerebrospinal Fluid

Pulmonary Tuberculosis

Top Venues

CPT: pharmacometrics & systems pharmacology

Nature medicine

Microbiology spectrum

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Caryn M Upton, Lubbe Wiesner, Kelly E Dooley, Gary Maartens
Cerebrospinal Fluid and Tuberculosis Meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology (2023)
Rob Christiaan van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, Caryn M Upton, Andreas H Diacon, Ulrika S H Simonsson
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19. Scientific reports 13 (1) (2023)
Irina Kontsevaya, Jan Heyckendorf, Frauke Koops, Doris Hillemann, Torsten Goldmann, Caryn M Upton, Veronique De Jager, Andreas Diacon, Christoph Lange
Transrenal Mycobacterium tuberculosis DNA in pulmonary tuberculosis patients during the first 14 days of treatment. Microbiology spectrum (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Simon E Koele, Thomas P C Dorlo, Caryn M Upton, Rob E Aarnoutse, Elin M Svenson
Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. CPT: pharmacometrics & systems pharmacology 13 (3) (2023)
Soyeon Kim, Xingye Wu, Michael D Hughes, Caryn M Upton, Kim Narunsky, Alberto Mendoza-Ticona, Saltnat Khajenoori, Pedro Gonzales, Sharlaa Badal-Faesen, Justin Shenje, Ayotunde Omoz-Oarhe, Vanessa Rouzier, Anthony J Garcia-Prats, Anne-Marie Demers, Linda Naini, Elizabeth Smith, Gavin Churchyard, Susan Swindells, N Sarita Shah, Amita Gupta, Anneke C Hesseling, null null
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. The Pediatric infectious disease journal 41 (5) (2022)
Caryn M Upton, Chanel I Steele, Gary Maartens, Andreas H Diacon, Lubbe Wiesner, Kelly E Dooley
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). The Journal of antimicrobial chemotherapy 77 (6) (2022)
Solomon P le Roux, Caryn M Upton, Naadira Vanker, Kelly E Dooley, Andreas H Diacon, null null
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity. American journal of respiratory and critical care medicine 203 (5) (2021)